- Home
- KRC vs IRTC Comparison
KRC vs IRTC Comparison
Compare KRC & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRC
- IRTC
- Stock Information
- Founded
- KRC 1947
- IRTC 2006
- Country
- KRC United States
- IRTC United States
- Employees
- KRC N/A
- IRTC N/A
- Industry
- KRC Real Estate Investment Trusts
- IRTC Medical/Dental Instruments
- Sector
- KRC Real Estate
- IRTC Health Care
- Exchange
- KRC Nasdaq
- IRTC Nasdaq
- Market Cap
- KRC 5.0B
- IRTC 5.8B
- IPO Year
- KRC 1997
- IRTC 2016
- Fundamental
- Price
- KRC $40.75
- IRTC $179.08
- Analyst Decision
- KRC Hold
- IRTC Strong Buy
- Analyst Count
- KRC 12
- IRTC 13
- Target Price
- KRC $39.92
- IRTC $180.23
- AVG Volume (30 Days)
- KRC 1.6M
- IRTC 336.6K
- Earning Date
- KRC 10-27-2025
- IRTC 10-29-2025
- Dividend Yield
- KRC 5.35%
- IRTC N/A
- EPS Growth
- KRC 9.52
- IRTC N/A
- EPS
- KRC 1.84
- IRTC N/A
- Revenue
- KRC $1,137,053,000.00
- IRTC $657,227,000.00
- Revenue This Year
- KRC N/A
- IRTC $25.17
- Revenue Next Year
- KRC $5.73
- IRTC $16.97
- P/E Ratio
- KRC $21.94
- IRTC N/A
- Revenue Growth
- KRC 2.26
- IRTC 22.37
- 52 Week Low
- KRC $27.07
- IRTC $55.92
- 52 Week High
- KRC $45.03
- IRTC $187.57
- Technical
- Relative Strength Index (RSI)
- KRC 42.34
- IRTC 58.27
- Support Level
- KRC $39.89
- IRTC $176.39
- Resistance Level
- KRC $42.92
- IRTC $180.81
- Average True Range (ATR)
- KRC 0.98
- IRTC 5.45
- MACD
- KRC -0.36
- IRTC -0.13
- Stochastic Oscillator
- KRC 31.62
- IRTC 86.95
About KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About IRTC iRhythm Technologies Inc.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.